psychedelics Archives -

Beckley adds digital element to its psychedelic drug trials

Phil Taylor Beckley Psytech, depression, digital, digital health, patient monitoring, psychedelics, wearable 0 Comment

Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring,

Beckley adds digital element to its psychedelic drug trials

https://pharmaphorum.com/news/beckley-adds-digital-element-to-its-psychedelic-drug-trials/

R&D/ Views & Analysis/ Views and analysis

Can psychedelics provide breakthrough in mental health?

Ben Hargreaves DMT, LSD, psilocybin, psychedelics, WHO 0 Comment

There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they

Can psychedelics provide breakthrough in mental health?

https://pharmaphorum.com/r-d/can-psychedelics-provide-breakthrough-in-mental-health/

News/ News/ R&D

Otsuka dips its toe in psychedelic waters, backing Mindset Pharma

Phil Taylor investment, Mindset Pharma, Otsuka, partnering, psychedelics 0 Comment

Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary

Otsuka dips its toe in psychedelic waters, backing Mindset Pharma

https://pharmaphorum.com/news/otsuka-dips-its-toe-in-psychedelic-waters-backing-mindset-pharma/

Digital/ News/ News

Mydecine, Maya team up on digital tools for psychedelic drugs

Phil Taylor digital, digital health, Maya Health, Mydecine, psychedelics 0 Comment

Psychedelic medicines developer Mydecine has joined forces with digital health company Maya to make digital tools that will

Mydecine, Maya team up on digital tools for psychedelic drugs

https://pharmaphorum.com/news/mydecine-maya-team-up-on-digital-tools-for-psychedelic-drugs/

News/ News/ R&D

Compass points to positive psilocybin trial, but shares fall

Phil Taylor Compass Pathways, depression, psychedelics, Psychiatry 0 Comment

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was

Compass points to positive psilocybin trial, but shares fall

https://pharmaphorum.com/news/compass-points-to-positive-psilocybin-trial-but-shares-fall/

News/ News/ R&D

Psychedelics startup Beckley attracts Janssen neuroscience VP

Phil Taylor appointment, Beckley Psytech, Janssen, psychedelics, senior management 0 Comment

Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen’s neuroscience division to take on the

Psychedelics startup Beckley attracts Janssen neuroscience VP

https://pharmaphorum.com/news/psychedelics-startup-beckley-attracts-janssen-neuroscience-vp/

News/ News/ R&D

First subject dosed in psilocybin trial for rare headache disorder

Phil Taylor Beckley Psytech, central nervous system, neurology, psychedelics, Psychiatry 0 Comment

The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial

First subject dosed in psilocybin trial for rare headache disorder

https://pharmaphorum.com/news/first-subject-dosed-in-psilocybin-trial-for-rare-headache-disorder/

News/ News/ R&D

Beckley Psytech raises $80m for psychedelic meds development

Phil Taylor Beckley Psytech, central nervous system, neurology, psychedelics, Psychiatry 0 Comment

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed

Beckley Psytech raises $80m for psychedelic meds development

https://pharmaphorum.com/news/beckley-psytech-raises-80m-for-psychedelic-meds-development/

News/ News/ R&D

MDMA on track for 2023 approval as PTSD therapy, says developer

Phil Taylor fda, MAPS, MDMA, psychedelics, PTSD 0 Comment

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp

MDMA on track for 2023 approval as PTSD therapy, says developer

https://pharmaphorum.com/news/mdma-on-track-for-2023-approval-as-ptsd-therapy-says-developer/

Trending

psychedelics

Login